Jennifer A. Pietenpol, Ph.D.
Director, Vanderbilt-Ingram Cancer Center
Benjamin F. Byrd, Jr. Professor of Oncology
Professor of Biochemistry, Cancer Biology and Otolaryngology
Vanderbilt University Medical Center
652 Preston Research Building
Nashville, TN 37232-0146
Jennifer A. Pietenpol, Ph.D., is the Director of the Vanderbilt-Ingram Cancer Center, the Benjamin F. Byrd, Jr. Professor of Molecular Oncology, and Professor of Biochemistry, Cancer Biology and Otolaryngology. Pietenpol’s research focuses on breast cancer and the p53 family signaling network—the most frequently targeted network for mutation in human tumors.
Read more ....
Jennifer A. Pietenpol, Ph.D., is the Director of the Vanderbilt-Ingram Cancer Center, the Benjamin F. Byrd, Jr. Professor of Molecular Oncology, and Professor of Biochemistry, Cancer Biology and Otolaryngology. Pietenpol’s research focuses on breast cancer and the p53 family signaling network—the most frequently targeted network for mutation in human tumors. Recently, Pietenpol has integrated her research expertise in tumor suppressor genes and molecular genetics with bioinformatic analysis of high dimensional genomic data sets to molecularly subtype difficult-to-treat, triple negative breast cancer. Her results are being translated to clinical trials and alignment of patients to appropriate, molecularly targeted therapy. Her research has impacted many areas of science and medicine and she has translated her discoveries into clinical impact for breast cancer patients. Pietenpol’s research is funded by the National Cancer Institute, the Susan G. Komen for the Cure Foundation, and the Department of Defense Breast Cancer Program.
In 2008, the President appointed Pietenpol to a six-year term on the National Cancer Advisory Board. Also, Dr. Pietenpol serves on the external advisory boards for eight NCI Comprehensive Cancer Centers and leads two as Chair. In 2011, Pietenpol was appointed as member of the Susan G. Komen for the Cure Foundation Scientific Advisory Committee and as a member of the Frederick National Laboratory for Cancer Research Advisory Committee. Recently, Dr. Pietenpol completed a three-year, elected term on the AACR Board of Directors. This year she will begin a three-year term as a Member of the Institute of Medicine, National Cancer Policy Forum.
In 1997, Pietenpol received the Burroughs Wellcome New Investigator Award in Toxicology; in 2004, she was honored with the Excellence in Teaching Award at Vanderbilt for her mentoring of graduate and medical students. She was inducted into the Johns Hopkins Society of Scholars (2009) and received the Carleton College Distinguished Alumni Achievement Award in 2011. In 2012, she was elected as a fellow of the American Association for the Advancement of Science for outstanding contributions to the field of cancer research, particularly the involvement of signaling networks in breast and other cancers.
After graduating from Carleton with honors in biology and as a member of Sigma Xi, Pietenpol earned a Ph.D. in cell biology at Vanderbilt University School of Medicine in 1990. She continued her postgraduate training at Johns Hopkins Oncology Center (now Sidney Kimmel Comprehensive Cancer Center) before returning to Vanderbilt in 1995 as an assistant professor of biochemistry. She achieved the rank of full professor in 2002. Pietenpol has served as associate editor or on the editorial board for numerous biomedical research journals. She has authored or co-authored over 120 articles published in the peer-reviewed scientific literature.
- B.A. - Carleton College, 1986
- Ph.D. - Vanderbilt University, 1990
- Fellowship - Johns Hopkins University, 1994
p53 family signaling axis (p53, p63, and p73); Breast Cancer; Mechanisms of tumor suppression and epithelial cell differentiation
Some defining properties of tumor cells are increased cell proliferation, decreased cell death and genomic instability. These characteristics are acquired as a consequence of mutations in genes that control the fidelity and frequency of cell division as well as the ability of the cell to initiate pathways of apoptosis. A goal of the ongoing cancer-based research in the Pietenpol Laboratory is to provide new therapeutic approaches that specifically target the molecular interactions and biochemical pathways that are changed in tumor cells. The Laboratory was one of the first to pioneer chromatin immunoprecipatation techniques allowing analysis of p53 and identification of target genes involved in tumor suppression. They discovered that p63 signaling confers key epithelial properties to cells by regulating novel target genes and transcriptional programs controling mesenchymal phenotypes. Subsequently, the Pietenpol group began mechanistic studies on p73, deciphered the functional p73 binding sites in the genome, discovered numerous p73-target mRNAs and microRNAs, and was the first to link the mTOR signaling pathway to regulation of p73 activity. Importantly, the research defined a mTOR-p73 signaling pathway involved in mesenchymal differentiation and a resulting p73 gene signature that classifies rhabdomyosarcomas by subtype and patient outcome. Most recently, Pietenpol and her team have integrated research expertise in tumor suppressor genes and molecular genetics with bioinformatic analysis of high dimensional genomic data sets to molecularly subtype difficult-to-treat, triple negative breast cancer. The results are being translated to clinical trials and alignment of patients to appropriate, molecularly targeted therapy. The overall goals of her research are to use bench-based discoveries to advance patient care.
- Barton, CE, Tahinci, E, Barbieri, CE, Johnson, KN, Hanson, AJ, Jernigan, KK, Chen, TW, Lee, E, Pietenpol, JA DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis. Dev Biol, 2009.
- Rosenbluth, JM, Pietenpol, JA mTOR regulates autophagy-associated genes downstream of p73. Autophagy, 5(1), 114-6, 2009.
- Rosenbluth, JM, Mays, DJ, Pino, MF, Tang, LJ, Pietenpol, JA A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol, 2008.
- Rosenbluth, JM, Pietenpol, JA The jury is in: p73 is a tumor suppressor after all. Genes Dev, 22(19), 2591-5, 2008.
- Brown, KA, Pietenpol, JA, Moses, HL A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem, 101(1), 9-33, 2007.
- Bonine-Summers, AR, Aakre, ME, Brown, KA, Arteaga, CL, Pietenpol, JA, Moses, HL, Cheng, N Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther, 6(4), 561-70, 2007.
- Perez, CA, Pietenpol, JA Transcriptional programs regulated by p63 in normal epithelium and tumors. Cell Cycle, 6(3), 246-54, 2007.
- Schavolt, KL, Pietenpol, JA p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis. Oncogene, 26(42), 6125-32, 2007.
- Perez, CA, Ott, J, Mays, DJ, Pietenpol, JA p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene, 26(52), 7363-70, 2007.
- Barbieri, CE, Tang, LJ, Brown, KA, Pietenpol, JA Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res, 66(15), 7589-97, 2006.
- Chakravarthy, AB, Kelley, MC, McLaren, B, Truica, CI, Billheimer, D, Mayer, IA, Grau, AM, Johnson, DH, Simpson, JF, Beauchamp, RD, Jones, C, Pietenpol, JA Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res, 12(5), 1570-6, 2006.
- Hinow, P, Rogers, CE, Barbieri, CE, Pietenpol, JA, Kenworthy, AK, DiBenedetto, E The DNA binding activity of p53 displays reaction-diffusion kinetics. Biophys J, 91(1), 330-42, 2006.
- Barbieri, CE, Pietenpol, JA p63 and epithelial biology. Exp Cell Res, 2006.
- Hearnes, JM, Mays, DJ, Schavolt, KL, Tang, L, Jiang, X, Pietenpol, JA Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol Cell Biol, 25(22), 10148-58, 2005.
- Barbieri, CE, Perez, CA, Johnson, KN, Ely, KA, Billheimer, D, Pietenpol, JA IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res, 65(6), 2314-20, 2005.
- Westfall, MD, Joyner, AS, Barbieri, CE, Livingstone, M, Pietenpol, JA Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle, 4(5), 710-6, 2005.
- Barbieri, CE, Pietenpol, JA p53 Family Members: Similar Biochemistry, Different Biology. Cancer Biol Ther, 4(4), 419-20, 2005.
- Sniezek, JC, Matheny, KE, Westfall, MD, Pietenpol, JA Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope, 114(12), 2063-72, 2004.
- Grandis, JR, Pietenpol, JA, Greenberger, JS, Pelroy, RA, Mohla, S Head and neck cancer: meeting summary and research opportunities. Cancer Res, 64(21), 8126-9, 2004.
- Brown, KA, Aakre, ME, Gorska, AE, Price, JO, Eltom, SE, Pietenpol, JA, Moses, HL Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res, 6(3), R215-31, 2004.
- Westfall, Matthew D., Pietenpol, Jennifer A. p63: molecular complexity in development and cancer. Carcinogenesis, 25857-864, 2004.
- Jo, Daewoong, Lin, Qing, Nashabi, Abudi, Mays, Deborah J, Unutmaz, Derya, Pietenpol, Jennifer A, Ruley, H Earl Cell cycle-dependent transduction of cell-permeant Cre recombinase proteins. J Cell Biochem, 89(4), 674-87, 2003.
- Stewart, Zoe A, Westfall, Matthew D, Pietenpol, Jennifer A Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci, 24139-45, 2003.
- Chakravarthy, Bapsi, Pietenpol, Jennifer A Combined modality management of breast cancer: development of predictive markers through proteomics. Semin Oncol, 30(4 Suppl 9), 23-36, 2003.
- Barbieri, Christopher E, Barton, Christopher E, Pietenpol, Jennifer A Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem, 278(51), 51408-14, 2003.
- Matheny, Keith E, Barbieri, Christopher E, Sniezek, Joseph C, Arteaga, Carlos L, Pietenpol, Jennifer A Inhibition of Epidermal Growth Factor Receptor Signaling Decreases p63 Expression in Head and Neck Squamous Carcinoma Cells. Laryngoscope, 113936-9, 2003.
- Anwar, Adil, Dehn, Donna, Siegel, David, Kepa, Jadwiga K, Tang, Luo Jia, Pietenpol, Jennifer A, Ross, David Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem, 27810368-73, 2003.
- Massion, Pierre P, Taflan, Peter M, Jamshedur Rahman, S M, Yildiz, Pinar, Shyr, Yu, Edgerton, Mary E, Westfall, Matthew D, Roberts, John R, Pietenpol, Jennifer A, Carbone, David P, Gonzalez, Adriana L Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res, 63(21), 7113-21, 2003.
- Westfall, Matthew D, Mays, Deborah J, Sniezek, Joseph C, Pietenpol, Jennifer A The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol, 232264-76, 2003.
- Coleman, Sean C, Stewart, Zoe A, Day, Terry A, Netterville, James L, Burkey, Brian B, Pietenpol, Jennifer A Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. Arch Otolaryngol Head Neck Surg, 128(2), 167-76, 2002.
- Pietenpol, J A, Stewart, Z A Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology, 181-182475-81, 2002.
- Sniezek, Joseph C, Matheny, Keith E, Burkey, Brian B, Netterville, James L, Pietenpol, Jennifer A Expression of p63 and 14-3-3sigma in normal and hyperdifferentiated mucosa of the upper aerodigestive tract. Otolaryngol Head Neck Surg, 126(6), 598-601, 2002.
- Pawlak, Maciej R, Banik-Maiti, Sarbani, Pietenpol, Jennifer A, Ruley, H Earl Protein arginine methyltransferase I: substrate specificity and role in hnRNP assembly. J Cell Biochem, 87(4), 394-407, 2002.
- Eichten, A, Westfall, M, Pietenpol, JA, MÃ¼nger, K Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology, 295(1), 74-85, 2002.
- Ji, C, Amarnath, V, Pietenpol, J A, Marnett, L J 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. Chem Res Toxicol, 14(8), 1090-6, 2001.
- Tahir, SK, Han, EK, Credo, B, Jae, HS, Pietenpol, JA, Scatena, CD, Wu-Wong, JR, Frost, D, Sham, H, Rosenberg, SH, Ng, SC A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res, 61(14), 5480-5, 2001.
- Stewart, Z A, Tang, L J, Pietenpol, J A Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene, 20(1), 113-24, 2001.
- Szak, S T, Mays, D, Pietenpol, J A Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol, 21(10), 3375-86, 2001.
- Flatt, P M, Pietenpol, J A Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Drug Metab Rev, 32(3-4), 283-305, 2001.
- Stewart, Z A, Pietenpol, J A Syk: a new player in the field of breast cancer. Breast Cancer Res, 3(1), 5-7, 2001.
- Stewart, Z A, Pietenpol, J A p53 Signaling and cell cycle checkpoints. Chem Res Toxicol, 14(3), 243-63, 2001.
- Song, S Y, Meszoely, I M, Coffey, R J, Pietenpol, J A, Leach, S D K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia, 2(3), 261-72, 2000.
- Flatt, P M, Tang, L J, Scatena, C D, Szak, S T, Pietenpol, J A p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol, 20(12), 4210-23, 2000.
- Flatt, P M, Polyak, K, Tang, L J, Scatena, C D, Westfall, M D, Rubinstein, L A, Yu, J, Kinzler, K W, Vogelstein, B, Hill, D E, Pietenpol, J A p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett, 156(1), 63-72, 2000.
- Stewart, Z A, Pietenpol, J A Cell cycle checkpoints as therapeutic targets. J Mammary Gland Biol Neoplasia, 4(4), 389-400, 1999.
- Stewart, Z A, Mays, D, Pietenpol, J A Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res, 59(15), 3831-7, 1999.
- Peek, R M, Blaser, M J, Mays, D J, Forsyth, M H, Cover, T L, Song, S Y, Krishna, U, Pietenpol, J A Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle. Cancer Res, 59(24), 6124-31, 1999.
- Szak, S.T. and Pietenpol, J.A "High affinity insertion/deletion lesion binding by p53: Evidence for a role of the p53 central domain." J. Biol. Chem., 2743904-3909, 1999.
- Szak, S T, Pietenpol, J A High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain. J Biol Chem, 274(6), 3904-9, 1999.
- NÃ¸rgaard, P, Law, B, Joseph, H, Page, D L, Shyr, Y, Mays, D, Pietenpol, J A, Kohl, N E, Oliff, A, Coffey, R J, Poulsen, H S, Moses, H L Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res, 5(1), 35-42, 1999.
- Stewart, Z A, Leach, S D, Pietenpol, J A p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol, 19(1), 205-15, 1999.
- Flatt, P.M., Price, J.O., and Pietenpol, J.A "Cell cycle response to DNA damage differs in normal human keratinocytes and fibroblasts." Cell Growth Diff., 9535-543, 1998.
- Flatt, P M, Price, J O, Shaw, A, Pietenpol, J A Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. Cell Growth Differ, 9(7), 535-43, 1998.
- Ji, C, Rouzer, C A, Marnett, L J, Pietenpol, J A Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Carcinogenesis, 19(7), 1275-83, 1998.
- Scatena, C D, Stewart, Z A, Mays, D, Tang, L J, Keefer, C J, Leach, S D, Pietenpol, J A Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem, 273(46), 30777-84, 1998.
- Leach, S D, Scatena, C D, Keefer, C J, Goodman, H A, Song, S Y, Yang, L, Pietenpol, J A Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res, 58(15), 3231-6, 1998.
- Jennings, M T, Pietenpol, J A The role of transforming growth factor beta in glioma progression. J Neurooncol, 36(2), 123-40, 1998.
- Koury, M J, Horne, D W, Brown, Z A, Pietenpol, J A, Blount, B C, Ames, B N, Hard, R, Koury, S T Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. Blood, 89(12), 4617-23, 1997.
- Ji, C, Marnett, L J, Pietenpol, J A Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels. Oncogene, 15(22), 2749-53, 1997.
- Pietenpol, J A A commentary on the 1996 American Association for Cancer Research Meeting--Cancer susceptibility genes and molecular carcinogenesis. Biochim Biophys Acta, 1288(1), R5-8, 1996.
- Pietenpol, JA, Lengauer, C, Jordan, J, Kinzler, KW, Vogelstein, B Mammalian cells resistant to tumor suppressor genes. Proc Natl Acad Sci U S A, 93(16), 8390-4, 1996.
- Pietenpol, JA, Bohlander, SK, Sato, Y, Papadopoulos, N, Liu, B, Friedman, C, Trask, BJ, Roberts, JM, Kinzler, KW, Rowley, JD Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res, 55(6), 1206-10, 1995.
- Sato, Y., Suto, Y., Pietenpol, J.A., Golub, T.R. Gilliland, G., Davis, E., Le Beau, M.M., Vogelstein, B., Rowley, J., Bohlander, S.K "TEL and KIPI define the smallest region of deletions on 12pl3 in hematopoietic malignancies." Blood, 861525-1533, 1995.
- Pietenpol, J.A., Papadopoulos, N., Markowitz, S., Willson, J.K.V., Kinzler, KW., and Vogelstein, B "Paradoxical inhibition of solid tumor cell growth by bcl2." Cancer Res, 543714-3717, 1994.
- Pietenpol, JA, Papadopoulos, N, Markowitz, S, Willson, JK, Kinzler, KW, Vogelstein, B Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res, 54(14), 3714-7, 1994.
- Pietenpol, JA, Tokino, T, Thiagalingam, S, el-Deiry, WS, Kinzler, KW, Vogelstein, B Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A, 91(6), 1998-2002, 1994.
- el-Deiry, WS, Harper, JW, O'Connor, PM, Velculescu, VE, Canman, CE, Jackman, J, Pietenpol, JA, Burrell, M, Hill, DE, Wang, Y WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res, 54(5), 1169-74, 1994.
- Oliner, JD, Pietenpol, JA, Thiagalingam, S, Gyuris, J, Kinzler, KW, Vogelstein, B Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362(6423), 857-60, 1993.
- Arteaga, C L, Carty-Dugger, T, Moses, H L, Hurd, S D, Pietenpol, J A Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ, 4(3), 193-201, 1993.
- Dagnino, L, Pietenpol, J A, Yang, E Y, Moses, H L Transforming growth factor regulation of keratinocyte growth. Recent Results Cancer Res, 12815-29, 1993.
- Pietenpol, JA, Vogelstein, B Tumour suppressor genes. No room at the p53 inn. Nature, 365(6441), 17-8, 1993.
- El-Delry, W.S., Kem, S.E., Pietenpol, J.A., Kinzler, K.W., and Vogelstein, B "Definition of consensus binding site for p53." Nat. Genet, 145-49, 1992.
- Kern, SE, Pietenpol, JA, Thiagalingam, S, Seymour, A, Kinzler, KW, Vogelstein, B Oncogenic forms of p53 inhibit p53-regulated gene expression. Science, 256(5058), 827-30, 1992.
- MÃ¼nger, K, Pietenpol, JA, Pittelkow, MR, Holt, JT, Moses, HL Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes. Cell Growth Differ, 3(5), 291-8, 1992.
- MÃ¼nger, K, Yee, CL, Phelps, WC, Pietenpol, JA, Moses, HL, Howley, PM Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J Virol, 65(7), 3943-8, 1991.
- Munger, K., Yee, C.L., Phelps, W.C., Pietenpol, J.A., Moses, H.L., and Howley, P.M "Biochemical and biological differences between E7 oncoproteins of the high- and low- risk human papillomavirus types are determined by amino-terminal sequences." J. of Virol, 653943-3948, 1991.
- Pietenpol, J A, MÃ¼nger, K, Howley, P M, Stein, R W, Moses, H L Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. Proc Natl Acad Sci U S A, 88(22), 10227-31, 1991.
- Moses, H L, Yang, E Y, Pietenpol, J A Regulation of epithelial proliferation by TGF-beta. Ciba Found Symp, 15766-74; discussion 75-80, 1991.
- Moses, H L, Pietenpol, J A, MÃ¼nger, K, Murphy, C S, Yang, E Y TGF beta regulation of epithelial cell proliferation: role of tumor suppressor genes. Princess Takamatsu Symp, 22183-95, 1991.
- Murphy, C S, Pietenpol, J A, MÃ¼nger, K, Howley, P M, Moses, H L c-myc and pRB: role in TGF-beta 1 inhibition of keratinocyte proliferation. Cold Spring Harb Symp Quant Biol, 56129-35, 1991.
- Pietenpol, JA, Stein, RW, Moran, E, Yaciuk, P, Schlegel, R, Lyons, RM, Pittelkow, MR, MÃ¼nger, K, Howley, PM, Moses, HL TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell, 61(5), 777-85, 1990.
- Moses, HL, Yang, EY, Pietenpol, JA TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell, 63(2), 245-7, 1990.
- Pietenpol, JA, Holt, JT, Stein, RW, Moses, HL Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci U S A, 87(10), 3758-62, 1990.
- Pietenpol, JA, Howe, PH, Cunningham, MR, Leof, EB Interferon alpha/beta modulation of growth-factor-stimulated mitogenicity in AKR-2B fibroblasts. J Cell Physiol, 141(3), 453-60, 1989.